Skip to content

To aim of this study is to determine the prevalence of Non-Alcoholic Fatty Liver Disease and Thyroid Dysfunction in Patients with Metabolic Syndrome.

A Cross-Sectional, Clinico-Epidemiological, Multicentre Study to Determine the Prevalence of Non-Alcoholic Fatty Liver Disease and Thyroid Dysfunction in Patients with Metabolic Syndrome, visiting the Endocrinology and Gastroenterology Out Patient Departments of Tertiary Health Care Centers in India.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2016/09/007270
Enrollment
400
Registered
2016-09-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with an established diagnosis of MetS as per the ATP III criteria and visiting the clinic as a part of their schedule

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Abbott India Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male and female patients, aged 18 to 65 years inclusive 2. Patients with an established diagnosis of MetS as per the ATP III criteria and visiting the clinic as a part of their schedule

Exclusion criteria

Exclusion criteria: 1. Patients with history of drug intake likely to cause NAFLD (e.g. aspirin, amiodarone, corticosteroids, methotrexate, 5-fluorouracil, tamoxifen, valproate, zidovudine, didanosine, diltiazem) or TD (e.g. interferon, molecular-targeted agents, amiodarone, thyroid hormone, anti-thyroid drugs, lithium, iodine, dopamine) 2. Patients with history of jejuno-ileal bypass or biliopancreatic diversion or extensive small bowel resection or total parenteral nutrition. 3. Evidence of other forms of chronic liver disease, suspected or confirmed hepatocellular carcinoma, known HIV positive 4. Female patients who are pregnant

Design outcomes

Primary

MeasureTime frame
1. Percentage of patients with NAFLD amongst the patients with MetS (diagnosed as per ATP III criteria), visiting the Endocrinology and Gastroenterology outpatient departments (OPD) in India. 2. Percentage of patients with TD amongst the patients with MetS (diagnosed as per ATP III criteria), visiting the Endocrinology and Gastroenterology outpatient departments (OPD) in India.Timepoint: 8 months recruitment period

Secondary

MeasureTime frame
1. Demographic characteristics, clinical and laboratory profile of Indian patients with MetS. 2. Percentage of patients categorized into high, intermediate and low probability for advanced fibrosis as per NFS 3. Percentage of TD patients with hyperthyroidism, subclinical hyperthyroidism, hypothyroidism and subclinical hypothyroidism Due to word limit the remaining 4 secondary endpoints have not been captured.Timepoint: 6 months

Countries

India

Contacts

Public ContactVishal Vaidya

Post Graduate Institute of Medical Education and Research (PGIMER)

ajayduseja@yahoo.co.in9417007416

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026